Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CASI CASI Pharmaceuticals	$1.89	$1.98	$1.64 ▼ $7.67	$23.25M	0.81	80,170 shs	9,848 shs
INBP Integrated BioPharma	$0.30 -10.7%	$0.31	$0.16 ▼ $0.42	$9.20M	0.8	21,940 shs	24,748 shs
INKT MiNK Therapeutics	$7.14 -2.1%	$7.79	$4.56 ▼ $13.79	$28.44M	0.16	12,164 shs	2,912 shs
VNRX VolitionRx	$0.49 -0.5%	$0.50	$0.40 ▼ $0.90	$50.38M	1	184,327 shs	22,956 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CASI CASI Pharmaceuticals	-1.85%	-3.39%	-8.62%	-21.40%	-49.73%
INBP Integrated BioPharma	-10.74%	-8.03%	+1.17%	+8.24%	+21.40%
INKT MiNK Therapeutics	-2.61%	-7.79%	-5.14%	-23.31%	-24.47%
VNRX VolitionRx	+1.49%	-3.87%	+6.20%	-23.08%	-27.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CASI CASI Pharmaceuticals	3.923 of 5 stars	3.5	3.0	0.0	4.3	2.6	1.7	0.0
INBP Integrated BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INKT MiNK Therapeutics	2.5281 of 5 stars	3.5	4.0	0.0	0.0	1.4	1.7	0.6
VNRX VolitionRx	1.7707 of 5 stars	3.3	0.0	0.0	0.0	2.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CASI CASI Pharmaceuticals	3.00	Buy	$4.00	111.64% Upside
INBP Integrated BioPharma	0.00	N/A	N/A	N/A
INKT MiNK Therapeutics	3.00	Buy	$37.50	425.58% Upside
VNRX VolitionRx	2.67	Moderate Buy	$3.75	666.87% Upside

Current Analyst Ratings Breakdown

Latest INBP, VNRX, CASI, and INKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/30/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/9/2025	CASI CASI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $4.00
4/8/2025	VNRX VolitionRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$2.50 ➝ $2.50
3/31/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/20/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/18/2025	INKT MiNK Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
3/12/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/4/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CASI CASI Pharmaceuticals	$31.37M	0.74	N/A	N/A	$1.81 per share	1.04
INBP Integrated BioPharma	$50.32M	0.18	$0.04 per share	7.35	$0.65 per share	0.47
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	($5.23) per share	N/A
VNRX VolitionRx	$1.31M	38.50	N/A	N/A	($0.11) per share	-4.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CASI CASI Pharmaceuticals	-$26.94M	-$2.55	N/A	∞	N/A	-143.18%	-181.52%	-45.72%	8/15/2025 (Estimated)
INBP Integrated BioPharma	$110K	$0.04	10.12	∞	N/A	1.78%	4.79%	3.54%	N/A
INKT MiNK Therapeutics	-$22.46M	-$2.52	N/A	N/A	N/A	N/A	N/A	-189.14%	8/12/2025 (Estimated)
VNRX VolitionRx	-$35.32M	-$0.27	N/A	∞	N/A	-2,321.14%	N/A	-163.39%	N/A

Latest INBP, VNRX, CASI, and INKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/16/2025	Q1 2025	CASI CASI Pharmaceuticals	-$0.61	-$0.69	-$0.08	-$0.69	$7.39 million	$6.24 million
5/15/2025	Q1 2025	INKT MiNK Therapeutics	-$0.61	-$0.70	-$0.09	-$0.70	N/A	N/A
5/14/2025	Q3 2025	INBP Integrated BioPharma	N/A	$0.02	N/A	$0.02	N/A	$13.95 million
3/31/2025	Q4 2024	CASI CASI Pharmaceuticals	-$0.60	-$0.79	-$0.19	-$0.79	$7.39 million	$13.36 million
3/18/2025	Q4 2024	INKT MiNK Therapeutics	-$0.50	-$0.62	-$0.12	-$0.62	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
INBP Integrated BioPharma	N/A	N/A	N/A	N/A	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CASI CASI Pharmaceuticals	1.38	3.20	2.32
INBP Integrated BioPharma	N/A	3.26	1.27
INKT MiNK Therapeutics	N/A	0.89	0.89
VNRX VolitionRx	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CASI CASI Pharmaceuticals	22.23%
INBP Integrated BioPharma	25.25%
INKT MiNK Therapeutics	2.87%
VNRX VolitionRx	8.09%

Insider Ownership

Company	Insider Ownership
CASI CASI Pharmaceuticals	21.24%
INBP Integrated BioPharma	67.20%
INKT MiNK Therapeutics	22.48%
VNRX VolitionRx	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CASI CASI Pharmaceuticals	180	12.30 million	12.20 million	Optionable
INBP Integrated BioPharma	150	30.30 million	9.94 million	Not Optionable
INKT MiNK Therapeutics	30	3.99 million	3.15 million	No Data
VNRX VolitionRx	80	103.02 million	80.80 million	Optionable

INBP, VNRX, CASI, and INKT Headlines

Recent News About These Companies

VolitionRX shares hold as Benchmark maintains rating

May 21, 2025 | uk.investing.com

VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript

May 20, 2025 | msn.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Insider Acquires 50,000 Shares of Stock

May 20, 2025 | insidertrades.com

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 19, 2025 | prnewswire.com

VolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advances

May 16, 2025 | msn.com

VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript

May 16, 2025 | seekingalpha.com

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

May 15, 2025 | prnewswire.com

Lagoda Investment Management L.P. Has $4.55 Million Position in VolitionRx Limited (NYSE:VNRX)

May 14, 2025 | marketbeat.com

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

May 12, 2025 | prnewswire.com

StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

May 9, 2025 | marketbeat.com

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

May 7, 2025 | prnewswire.com

VolitionRx's (VNRX) Buy Rating Reiterated at D. Boral Capital

May 2, 2025 | marketbeat.com

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

April 29, 2025 | prnewswire.com

VolitionRx enters new sales agreement, terminates old one

April 24, 2025 | investing.com

VolitionRx initiated with a Buy at H.C. Wainwright

April 8, 2025 | markets.businessinsider.com

HC Wainwright & Co. Initiates Coverage of VolitionRx (VNRX) with Buy Recommendation

April 8, 2025 | msn.com

Earnings call transcript: VolitionRx revenue beats forecast in Q4 2024

April 2, 2025 | investing.com

VolitionRx outlines 2025 licensing goals and targets cash neutrality with strategic expansions

April 1, 2025 | msn.com

VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript

April 1, 2025 | seekingalpha.com

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

March 31, 2025 | prnewswire.com

3VNRX : A Look Ahead: VolitionRX's Earnings Forecast

March 28, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Archer Posts Surprise Q1 Beat, Sets Stage for 2025 Revenue Launch
By Jeffrey Neal Johnson | May 14, 2025
View Archer Posts Surprise Q1 Beat, Sets Stage for 2025 Revenue Launch
Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer
By Jeffrey Neal Johnson | May 14, 2025
View Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer

INBP, VNRX, CASI, and INKT Company Descriptions

CASI Pharmaceuticals NASDAQ:CASI

$1.89 0.00 (0.00%)

As of 11:39 AM Eastern

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Integrated BioPharma OTCMKTS:INBP

$0.30 -0.04 (-10.74%)

As of 05/28/2025 03:34 PM Eastern

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

MiNK Therapeutics NASDAQ:INKT

$7.14 -0.16 (-2.13%)

As of 11:51 AM Eastern

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

VolitionRx NYSE:VNRX

$0.49 0.00 (-0.55%)

As of 11:39 AM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time